Adjunct to a reduced-calorie diet & increased physical activity for wt management in adults w/ initial BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 to <30 kg/m2 (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. Adjunct to a healthy nutrition & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points) & body wt >60 kg.
SCAdult & adolescent ≥12 yr Initially, 0.6 mg once daily. Increase to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval to improve GI tolerability. Maintenance dose: 3 mg daily.
Do not administer as IV/IM. Do not use as substitute for insulin in patients w/ DM. Not recommended in patients w/ CHF NYHA class IV; treatment w/ other products for wt management; obesity secondary to endocrinological or eating disorders or to treatment w/ medicinal products that may cause wt gain; inflammatory bowel disease & diabetic gastroparesis. Discontinue & do not restart treatment if pancreatitis & acute pancreatitis is confirmed. Cholelithiasis & cholecystitis. Thyroid disease. Monitor heart rate regularly. Discontinue if clinically relevant sustained increase in resting heart rate is experienced. Risk of dehydration & fluid depletion. Do not use in combination w/ another GLP-1 receptor agonist. Concomitant use w/ insulin &/or sulfonylurea. May affect ability to drive & use machines. Mild or moderate hepatic impairment. Not recommended in patients w/ severe hepatic & renal impairment (CrCl <30 mL/min) & ESRD. Not to be used during pregnancy & lactation. Childn <12 yr. Elderly ≥75 yr.
Sign Out
